

Immunochemistry, Division of Transfusion Transmitted Diseases.

*Closed committee deliberations.* The committee will discuss the intramural scientific program. This portion of the meeting will be closed to prevent disclosure of personal information concerning individuals associated with the research program, disclosure of which would constitute a clearly unwarranted invasion of personal privacy (5 U.S.C. 552b(c)(6)).

Each public advisory committee meeting listed above may have as many as four separable portions: (1) An open public hearing, (2) an open committee discussion, (3) a closed presentation of data, and (4) a closed committee deliberation. Every advisory committee meeting shall have an open public hearing portion. Whether or not it also includes any of the other three portions will depend upon the specific meeting involved. The dates and times reserved for the separate portions of each committee meeting are listed above.

The open public hearing portion of each meeting shall be at least 1 hour long unless public participation does not last that long. It is emphasized, however, that the 1 hour time limit for an open public hearing represents a minimum rather than a maximum time for public participation, and an open public hearing may last for whatever longer period the committee chairperson determines will facilitate the committee's work.

Public hearings are subject to FDA's guideline (subpart C of 21 CFR part 10) concerning the policy and procedures for electronic media coverage of FDA's public administrative proceedings, including hearings before public advisory committees under 21 CFR part 14. Under 21 CFR 10.205, representatives of the electronic media may be permitted, subject to certain limitations, to videotape, film, or otherwise record FDA's public administrative proceedings, including presentations by participants.

Meetings of advisory committees shall be conducted, insofar as is practical, in accordance with the agenda published in this Federal Register notice. Changes in the agenda will be announced at the beginning of the open portion of a meeting.

Any interested person who wishes to be assured of the right to make an oral presentation at the open public hearing portion of a meeting shall inform the contact person listed above, either orally or in writing, prior to the meeting. Any person attending the hearing who does not in advance of the meeting request an opportunity to speak will be allowed to make an oral presentation at the

hearing's conclusion, if time permits, at the chairperson's discretion.

The agenda, the questions to be addressed by the committee, and a current list of committee members will be available at the meeting location on the day of the meeting.

Transcripts of the open portion of the meeting may be requested in writing from the Freedom of Information Office (HFI-35), Food and Drug Administration, rm. 12A-16, 5600 Fishers Lane, Rockville, MD 20857, approximately 15 working days after the meeting, at a cost of 10 cents per page. The transcript may be viewed at the Dockets Management Branch (HFA-305), Food and Drug Administration, rm. 1-23, 12420 Parklawn Dr., Rockville, MD 20857, approximately 15 working days after the meeting, between the hours of 9 a.m. and 4 p.m., Monday through Friday. Summary minutes of the open portion of the meeting may be requested in writing from the Freedom of Information Office (address above) beginning approximately 90 days after the meeting.

The Commissioner has determined for the reasons stated that those portions of the advisory committee meetings so designated in this notice shall be closed. The Federal Advisory Committee Act (FACA) (5 U.S.C. app. 2, 10(d)), permits such closed advisory committee meetings in certain circumstances. Those portions of a meeting designated as closed, however, shall be closed for the shortest possible time, consistent with the intent of the cited statutes.

The FACA, as amended, provides that a portion of a meeting may be closed where the matter for discussion involves a trade secret; commercial or financial information that is privileged or confidential; information of a personal nature, disclosure of which would be a clearly unwarranted invasion of personal privacy; investigatory files compiled for law enforcement purposes; information the premature disclosure of which would be likely to significantly frustrate implementation of a proposed agency action; and information in certain other instances not generally relevant to FDA matters.

Examples of portions of FDA advisory committee meetings that ordinarily may be closed, where necessary and in accordance with FACA criteria, include the review, discussion, and evaluation of drafts of regulations or guidelines or similar preexisting internal agency documents, but only if their premature disclosure is likely to significantly frustrate implementation of proposed agency action; review of trade secrets and confidential commercial or financial information submitted to the

agency; consideration of matters involving investigatory files compiled for law enforcement purposes; and review of matters, such as personnel records or individual patient records, where disclosure would constitute a clearly unwarranted invasion of personal privacy.

Examples of portions of FDA advisory committee meetings that ordinarily shall not be closed include the review, discussion, and evaluation of general preclinical and clinical test protocols and procedures for a class of drugs or devices; consideration of labeling requirements for a class of marketed drugs or devices; review of data and information on specific investigational or marketed drugs and devices that have previously been made public; presentation of any other data or information that is not exempt from public disclosure pursuant to the FACA, as amended; and, deliberation to formulate advice and recommendations to the agency on matters that do not independently justify closing.

This notice is issued under section 10(a)(1) and (2) of the Federal Advisory Committee Act (5 U.S.C. app. 2), and FDA's regulations (21 CFR part 14) on advisory committees.

Dated: November 14, 1995.  
David A. Kessler,  
*Commissioner of Food and Drugs.*  
[FR Doc. 95-28521 Filed 11-21-95; 8:45 am]  
BILLING CODE 4160-01-F

## National Institutes of Health

### Meeting of the Advisory Committee to the Director, NIH

Pursuant to Public Law 92-463, notice is hereby given of the meeting of the Advisory Committee to the Director, NIH, December 7, 1995, Conference Room 10, Building 31, National Institutes of Health, Bethesda, Maryland 20892.

The entire meeting will be open to the public from 8:30 a.m. to adjournment. The topics proposed for discussion include (1) Report from the Recombinant DNA Ad Hoc Committee; (2) Report and Recommendations from the Panel to Assess the NIH Investment in Research on Gene Therapy; (3) Report from the Economics Roundtable; (4) Status Report from the Clinical Research Panel; and (5) Preliminary Report on the Study of Options Regarding the Clinical Center. Attendance by the public will be limited to space available.

Ms. Janice Ramsden, Program Assistant, Office of the Deputy Director, National Institutes of Health, 1 Center

Drive MSC 0159, Bethesda, Maryland 20892-0159, telephone (301) 496-0959, fax (301) 496-7451, will furnish the meeting agenda, roster of committee members, and substantive program information upon request. Any individual who requires special assistance, such as sign language interpretation or other reasonable accommodations, should contact Ms. Ramsden no later than November 28, 1995.

Dated: November 13, 1995.

Margery G. Grubb,

*Senior Committee Management Specialist,  
National Institutes of Health.*

[FR Doc. 95-28442 Filed 11-21-95; 8:45 am]

**BILLING CODE 4140-01-M**

### **National Cancer Institute; Closed Meeting**

Pursuant to Section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following meeting of the National Cancer Institute Initial Review Group:

*Agenda/Purpose:* To review and evaluate grant applications.

*Committee Name:* Subcommittee A—Cancer Centers.

*Date:* December 8, 1995.

*Time:* 7:30 a.m.

*Place:* Bethesda Ramada Inn, Bethesda, MD 20814.

*Contact Person:* David E. Maslow, Ph.D., 6130 Executive Blvd., Room 643A, Bethesda, MD 20892, Telephone: 301-496-2330.

The meeting will be closed in accordance with the provisions set forth in secs. 552b(c)(4) and 552(c)(6), Title 5, U.S.C. Applications and/or proposals and the discussions could reveal confidential trade secrets or commercial property such as patentable material and personal information concerning individuals associated with the applications and/or proposals, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

(Catalog of Federal Domestic Assistance Program Numbers: 93.393, Cancer Cause and Prevention Research; 93.394, Cancer Detection and Diagnosis Research; 93.395, Cancer Treatment Research; 93.396, Cancer Biology Research; 93.397, Cancer Centers Support; 93.398, Cancer Research Manpower; 93.399, Cancer Control.)

Dated: November 13, 1995.

Margery G. Grubb,

*Senior Committee Management Specialist,  
National Institutes of Health.*

[FR Doc. 95-28443 Filed 11-21-95; 8:45 am]

**BILLING CODE 4140-01-M**

### **National Institute of Mental Health; Closed Meetings**

Pursuant to Section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following meetings of the National Institutes of Mental Health Special Emphasis Panel:

*Agenda/Purpose:* To review and evaluate grant applications.

*Committee Name:* National Institute of Mental Health Special Emphasis Panel.

*Date:* November 29, 1995.

*Time:* 2 p.m.

*Place:* Parklawn Building, Room 9-101, 5600 Fishers Lane, Rockville, MD 20857.

*Contact Person:* Shirley H. Maltz, Parklawn Building, Room 9-101, 5600 Fishers Lane, Rockville, MD 20857, Telephone: 301, 443-3936.

*Committee Name:* National Institute of Mental Health Special Emphasis Panel.

*Date:* December 7, 1995.

*Time:* 11 a.m.

*Place:* Parklawn Building, Room 9-101, 5600 Fishers Lane, Rockville, MD 20857.

*Contact Person:* Shirley H. Maltz, Parklawn Building, Room 9-101, 5600 Fishers Lane, Rockville, MD 20857, Telephone: 301, 443-3936.

*Committee Name:* National Institute of Mental Health Special Emphasis Panel.

*Date:* December 12, 1995.

*Time:* 1 p.m.

*Place:* Parklawn Building, Room 9-101, 5600 Fishers Lane, Rockville, MD 20857.

*Contact Person:* Shirley H. Maltz, Parklawn Building, Room 9-101, 5600 Fishers Lane, Rockville, MD 20857, Telephone: 301, 443-3936.

The meetings will be closed in accordance with the provisions set forth in secs. 552b(c)(4) and 552(c)(6), Title 5, U.S.C. Applications and/or proposals and the discussions could reveal confidential trade secrets or commercial property such as patentable material and personal information concerning individuals associated with the applications and/or proposals, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

This notice is being published less than fifteen days prior to the first meeting due to the urgent need to meet timing limitations imposed by the review and funding cycle.

(Catalog of Federal Domestic Assistance Program Numbers 93.242, 93.281, 93.282)

Dated: November 9, 1995.

Susan K. Feldman,

*Committee Management Officer, National Institutes of Health.*

[FR Doc. 95-28444 Filed 11-21-95; 8:45 am]

**BILLING CODE 4140-01-M**

### **DEPARTMENT OF THE INTERIOR**

#### **National Park Service**

#### **National Register of Historic Places; Notification of Pending Nominations**

Nominations for the following properties being considered for listing in the National Register were received by the National Park Service before November 11, 1995. Pursuant to § 60.13 of 36 CFR part 60 written comments concerning the significance of these properties under the National Register criteria for evaluation may be forwarded to the National Register, National Park Service, PO Box 37127, Washington, DC 20013-7127. Written comments should be submitted by December 7, 1995.

Carol D. Skull,

*Keeper of the National Register.*

#### **ARKANSAS**

##### **Cleburne County**

Olmstead, T. E., & Son Funeral Home, 108 S. Fourth St., Heber Springs, 95001438

##### **Poinsett County**

Bacon Hotel, Homestead Rd. at jct. with RR tracks, SE corner, Whitehall, 95001437

#### **MASSACHUSETTS**

##### **Worcester County**

Brown—Davis—Frost Farm, 17 Whitney St., Town of Holden, Jefferson, 95001444

Hubbard—Dawson House, 925 Main St., Holden, 95001443

Manning—Ball House, 370 Manning St., Town of Holden, Jefferson, 95001442

Stony Farm, 428 Salisbury St., Holden, 95001441

#### **NEW MEXICO**

##### **Lea County**

Pyburn House, 203 Fourth St., Lovington, 95001429

#### **NORTH CAROLINA**

##### **Guilford County**

Deep River Friends Meeting House and Cemetery, 5300 W. Wendover Ave., High Point, 95001448

##### **Wake County**

Haywood, Dr. Hubert Benbury, House, 634 N. Blount St., Raleigh, 95001440

#### **SOUTH DAKOTA**

##### **Bon Homme County**

Scotland Residential Historic District,